Norman D J
Department of Medicine, Oregon Health Sciences University, Portland 97201.
Transplant Proc. 1988 Dec;20(6):1248-52.
The murine monoclonal anti-T cell antibody, OKT3, has been used during the past 6 years in various clinical transplantation studies. Undoubtedly it has proved to be the most effective and specific immunosuppressive drug widely available for use in organ transplantation. However, because of problems of first-dose symptoms, recurrent rejection, and antibody production, currently used protocols with OKT3 might not be the final answer in immunosuppressive therapy. OKT3 is an important prototype of future monoclonal antibodies and can be considered the gold standard against which newer drugs must be compared.
鼠单克隆抗T细胞抗体OKT3在过去6年中已用于各种临床移植研究。毫无疑问,它已被证明是器官移植中广泛可用的最有效、最具特异性的免疫抑制药物。然而,由于首剂症状、反复排斥反应和抗体产生等问题,目前使用OKT3的方案可能并非免疫抑制治疗的最终答案。OKT3是未来单克隆抗体的重要原型,可被视为必须与新药进行比较的金标准。